Springwind

Springwind Pharmaceutical, also known as Chunfeng Pharmaceutical, is a Beijing-based pharmaceutical company that integrates the research, development, production, and sale of both modern chemical drugs and Traditional Chinese Medicine (TCM). The company gained significant prominence for its development and production of Jinhua Qinggan Granules, which were widely utilized during the COVID-19 pandemic in China. Beyond its TCM portfolio, Springwind operates a dedicated chemical drug division focused on therapeutic areas such as respiratory health, cardiovascular diseases, and oncology. The company maintains a robust manufacturing infrastructure and a research institute aimed at modernizing traditional therapies through clinical evidence and advanced formulation technologies. Springwind is recognized as a National High-tech Enterprise in China, emphasizing its commitment to innovation in the domestic healthcare market.